Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology cipargamin - PfATP4 inhibitor NCT04675931 KARISMA (CKAE609B12201) Indication Malaria severe Phase 2 Phase Patients 252 2023 priorities Innovation: Clinical trials Primary Outcome Measures Arms Intervention Target Patients Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ] Arm 1: experimental, IV KAE609 Dose regimen 1 Arm 2: experimental, IV KAE609 Dose regimen 2 Arm 3: experimental, IV KAE609 Dose regimen 3 Arm 4: active comparator, IV Artesunate Arm 5: Coartem, Standard of care Patients with Malaria, severe Readout Milestone(s) 2024 Publication TBD Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 101 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation